Protease inhibitors for Covid-19: could disease severity have impacted results?
In early January, when the coronavirus outbreak was being watched as a developing global threat, AbbVie was one of the first companies to donate its HIV protease inhibitors combination therapy Aluvia (lopinavir / ritonavir), also known as Kaletra, to help China treat patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19.
Covid-19 pandemic interferes with ongoing clinical developments in female health
The female health space is facing pauses in drug development and certain treatments due to the Covid-19 pandemic. On 23 March, ObsEva provided an update regarding the impact of Covid-19 on the company’s clinical development programs.
The company stated that patient screening and randomisation in its ongoing Phase III trials of its oral GnRH receptor antagonist linzagolix for endometriosis-associated pain, EDELWEISS 2 and EDELWEISS 3, are voluntarily being paused until further notice.